Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma

Masatoshi Kudo

doi:10.1159/000531225

Related publications

Editorial Material2023

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma

Masatoshi Kudo

Article2020

IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation

Stephen P. Hack, Jessica Spahn, Minshan Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C. Yopp, Pierce K. H. Chow, Shukui Qin

Editorial Material2024

Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence

Masatoshi Kudo

Article2015

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T.P. Poon, Kwang–Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabrício Henrique Pereira De Souza, Marie-Aude Le Berre, Gerold Meinhardt, Josep M. Llovet

The Lancet Oncology

Article2021

P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation

Lipika Goyal, Arndt Vogel, Andrew X. Zhu, Ann‐Lii Cheng, Thomas Yau, Jian Zhou, Raul N. Uppot, Eunhee Kim, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo